PDE5A and endothelial dysfunction: Collectively, these results support the growing view that PDE5 inhibitors may hold therapeutic promise beyond vasodilation, with potential to be repositioned as adjunctive treatments in inflammation-driven diseases, particularly those characterised by endothelial dysfunction and chronic low-grade inflammation.